Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme

Alopecia Areata

Sustained hair regrowth with continued ritlecitinib treatment through Week 48 in patients with alopecia areata with or without early target responses: post hoc analysis of the ALLEGRO phase 2b/3 trial

J Am Acad Dermatol

Piliang M, Lynde C, King B, Mirmirani P, Sinclair R, Senna M, Forman S, Bordone L, De La Cueva Dobao P, Wolk R, Zwillich SH, Tran H, Wajsbrot D, Ahmed HM, Takiya L

doi: 10.1016/j.jaad.2024.09.064

Alopecia Areata

Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata

Br J Dermatol

Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, Magnolo N, Piraccini BM, Luo X, Wolk R, Woodworth D, Schaefer G, Lejeune A

doi: 10.1093/bjd/ljae365

Psoriatic Arthritis

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Ther Adv Musculoskelet Dis

Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA

doi: 10.1177/1759720X241288071

Psoriatic Arthritis

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

RMD Open

McInnes IB, Sewerin P, Sharaf M, Efficace M, Lavie F, Zimmermann M, Coates LC

doi: 10.1136/rmdopen-2024-004494

Alopecia Areata

Alopecia Areata-Specific Patient-Reported Outcome Measures: A Systematic Review

JAMA Dermatol

Darchini-Maragheh E, Moussa A, Yoong N, Bokhari L, Jones L, Sinclair R

doi: 10.1001/jamadermatol.2024.6660

Psoriatic Arthritis

Global Recruiting Patterns Affect Placebo Response Rates In Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis

Arthritis Rheumatol

Kerschbaumer A, Steiner M, Khalili S, Shehab A, Jordanov A, Wildner B, Maad M, Smolen JS, Aletaha D

doi: 10.1002/art.43302

Alopecia Areata

Quality of life, Psychosocial difficulties and Bullying in Pediatric Alopecia Areata Patients: A European Cross-Sectional Study

Br J Dermatol

Franz A, Constantinou A, Hillmann K, Chasapi V, Vañó Galván S, Leducq S, Maruani A, Abasq C, Piraccini BM, Rudnicka L, Prat Torres C, Starace M, Waskiel-Burnat A, Pfetsch J, Blume-Peytavi U

doi: 10.1093/bjd/ljaf318

Atopic Dermatitis

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Adv Ther

Ständer S, Yosipovitch G, Simpson EL, Kim BS, Kabashima K, Thaçi D, Metz M, Chen Z, Hagen S, Bastian M

doi: 10.1007/s12325-025-03124-8

Atopic Dermatitis

The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials

J Am Acad Dermatol

Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, Weidinger S, Bieber T, Hong HC, Elmaraghy H, Atwater AR, Pierce E, Xu C, Agell H, Gil EG, Simpson E

doi: 10.1016/j.jaad.2024.12.026

Related content

Sustained hair regrowth with continued ritlecitinib treatment through Week 48 in patients with alopecia areata with or without early target responses: post hoc analysis of the ALLEGRO phase 2b/3 trial

Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

Alopecia Areata-Specific Patient-Reported Outcome Measures: A Systematic Review

Global Recruiting Patterns Affect Placebo Response Rates In Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis

Quality of life, Psychosocial difficulties and Bullying in Pediatric Alopecia Areata Patients: A European Cross-Sectional Study

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials